Skip to main content
TipRanks
Go Ultimate75% OFF

DocGo (DCGO) Q3 2026 Earnings Report

606 Followers

DCGO Q3 2026 EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$0.28

DCGO Q3 2026 Revenue Results

Actual Revenue
$73.43M
Expected Revenue
$76.96M
Beat/Miss
Missed by -$3.53M
YoY Revenue Growth
+3.70%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/09/2026
Time
After Close
Conference Call
Monday, November 9, 2026
DCGO Upcoming Earnings

DocGo's next earnings date is estimated for March 15, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DCGO Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 09, 2026|% Change Since:-30.28%|
Earnings Call Sentiment|Positive

The call was broadly constructive, with substantial sequential improvement in adjusted EBITDA, gross margin, SG&A, transportation revenue, non-migrant Mobile Health growth, and operating efficiency. Management also outlined a path toward positive adjusted EBITDA in 2027 and continued progress on portfolio optimization. However, the company remains loss-making, reduced 2026 revenue guidance, reported declining cash, faced lower Mobile Health margins and elevated fuel costs, and is managing a CEO transition. Overall, the number and significance of the operational improvements outweighed the disclosed challenges.

Company Guidance

DocGo reaffirmed full year 2026 adjusted EBITDA guidance of a loss of $17 million-$22 million and revised revenue guidance to approximately $300 million, excluding any revenue from Hicuity Health; fourth-quarter revenue is expected to be somewhere in the $77 million, $78 million range or something like that, which management said looks very achievable. Medical transportation is expected to contribute about $205 million or so to $210 million, remote patient monitoring $16 million-$17 million, SteadyMD between $30 million and $35 million, mobile phlebotomy between $5 million and $6 million, clinical staffing about $14 million, $15 million, and Care in the Home probably $7 million or $8 million, maybe even as much as $9 million. For 2027, the company specifically did not issue guidance, but expects some solid revenue gains year-over-year, medical transportation growth at a high single-digit level, a little bit more moderated growth in Care in the Home, and some positive adjusted EBITDA for the full year; management also said positive operating cash flow might occur in Q1 or maybe even Q2.

  • Revenue Returned to Year-Over-Year GrowthThird-quarter revenue was $73.4 million, up 4% from $70.8 million in the third quarter of 2025. This was DocGo's first year-over-year revenue increase since the second quarter of 2023. Excluding $8.4 million of migrant-related revenue in the 2025 period, revenue increased 18% year over year; excluding both migrant-related revenue and SteadyMD revenue, revenue still increased approximately 5%.
  • Record Medical Transportation RevenueMedical transportation revenue reached $53.3 million, up 6.4% from $50.1 million in the third quarter of 2025 and setting a new quarterly record for DocGo. Growth came from both large and small U.S. markets, with particularly strong gains in New York City, Delaware, Wisconsin, and Tennessee.
  • Strong Growth in Non-Migrant Mobile Health RevenueMobile Health revenue was $20.2 million, including no migrant-related revenue, compared with $20.7 million in the prior-year quarter, which included $8.4 million of migrant-related revenue. Non-migrant Mobile Health revenue increased 64% year over year, driven by remote patient monitoring, mobile phlebotomy, and SteadyMD.
  • Adjusted EBITDA Loss Improved SignificantlyThird-quarter adjusted EBITDA was a loss of $3.2 million, compared with losses of $6.3 million in the second quarter, $10.2 million in the first quarter, and $7.2 million in the third quarter of 2025. Management described the quarter as the company's best EBITDA performance since the fourth quarter of 2024.
  • Gross Margin ExpansionConsolidated adjusted gross margin improved to 33.3% from 30.5% in the second quarter and 33.0% in the third quarter of 2025. Medical transportation adjusted gross margin increased to 34.7% from 31.7% a year earlier, and management estimated that transportation gross margin would have approached 37% excluding the Upstate New York market.
  • Lower Overtime and Improved Operating EfficiencyThe medical transportation overtime rate declined to near 10% in the third quarter, compared with nearly 14% throughout much of 2025. Management attributed the improvement to increased field headcount during the first half of 2026.
  • SG&A Declined SequentiallyAdjusted SG&A declined to $28.7 million from $29.7 million in the second quarter and $30.8 million in the first quarter. The improvement was driven in part by the June corporate workforce reduction, additional September reductions, vendor renegotiations, and operating-efficiency initiatives.
  • AI Initiatives Reduced Booking CostsDocGo launched automated outreach through AI voice agents for in-home visits, reducing cost per booking by over 50%. Management also said AI-based outreach optimization was being used to support more profitable scaling of Care in the Home.
  • Care in the Home Profitability ProgressAlthough Care in the Home is expected to incur an approximately $5 million loss in 2026, management said its profitability has improved significantly and that the business is expected to achieve positive adjusted EBITDA on a contribution basis late this year or very early next year, alongside substantial revenue growth in 2027.
  • Care in the Home Operating Model ImprovedDocGo reduced Care in the Home visit volume by approximately 26% in the third quarter while optimizing patient outreach and changing the field clinician mix to include LPNs, mobile phlebotomists, and medical assistants. Management said the changes lowered unit economic costs and are intended to support scaling in the fourth quarter, in 2027, and in a new Pennsylvania initiative.
  • Liquidity Support and Receivables Collection ProgressDocGo closed the first $12.5 million tranche of its Perceptive Advisors debt facility. An additional $12.5 million is available upon closing the Hicuity Health transaction, with another $25 million available subject to maintaining $130 million in Mobile Health revenue; current Mobile Health revenue including Hicuity was stated to be more than $150 million. DocGo also reported progress on approximately $19 million of longstanding receivables, including an approximately $6.7 million receivable expected to be collected imminently and a $12.6 million receivable likely to be resolved late this year or in early 2027.
  • Hicuity Health Transaction Remains on TrackManagement said the Hicuity Health acquisition was awaiting regulatory approval but remained on track to close at the end of November or early December 2026. Revenue guidance excludes any Hicuity contribution.
  • Positive 2027 EBITDA OutlookAlthough formal 2027 guidance was not issued, management said it expects solid year-over-year revenue gains, high single-digit growth in medical transportation, growth across Mobile Health business lines, and positive adjusted EBITDA for the full year 2027.
  • Profitability Threshold FrameworkManagement stated that approximately $240 million of the expected $300 million of 2026 revenue is EBITDA-contribution positive. Of the remaining $60 million, approximately one-third is expected to be shut down and approximately two-thirds is expected to be restructured or renegotiated to produce EBITDA in 2027.
  • Remote Patient Monitoring Positioned for CMS RequirementsManagement said CMS requirements linking remote patient monitoring enrollment to a physician visit align with DocGo's ability to provide both medical visits and patient monitoring. The primary implantable-device monitoring fee schedules, including pacemakers and loop recorders, were described as largely unchanged.

DCGO Earnings History

DCGO earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 15, 20272026 (Q4)-0.08--1.37――
Nov 09, 20262026 (Q3)-0.11-0.17-0.2839.29% (+0.11)
Aug 17, 20262026 (Q2)-0.10-0.16-0.11-45.45% (-0.05)
May 11, 20262026 (Q1)-0.12-0.15-0.09-66.67% (-0.06)
Mar 16, 20262025 (Q4)-0.14-1.37-0.03-4466.67% (-1.34)
Nov 10, 20252025 (Q3)-0.15-0.280.05-660.00% (-0.33)
Aug 07, 20252025 (Q2)-0.10-0.110.06-283.33% (-0.17)
May 08, 20252025 (Q1)-0.03-0.090.1-190.00% (-0.19)
Feb 27, 20252024 (Q4)0.04-0.030.07-140.00% (-0.10)
Nov 07, 20242024 (Q3)0.040.050.050.00% (+0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed